Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery

Reperfusion, despite being required for myocardial salvage, is associated with additional injury. We hypothesize that infarct size (IS) will be reduced by a period of bloodless reperfusion with hemoglobin-based oxygen carriers (HBOC) before blood-flow restoration. In the pig model, we first characte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Basic research in cardiology 2017-03, Vol.112 (2), p.17-17, Article 17
Hauptverfasser: García-Ruiz, Jose M., Galán-Arriola, Carlos, Fernández-Jiménez, Rodrigo, Aguero, Jaume, Sánchez-González, Javier, García-Alvarez, Ana, Nuno-Ayala, Mario, Dubé, Gregory P., Zafirelis, Zafiris, López-Martín, Gonzalo J., Bernal, Juan A., Lara-Pezzi, Enrique, Fuster, Valentín, Ibáñez, Borja
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 17
container_issue 2
container_start_page 17
container_title Basic research in cardiology
container_volume 112
creator García-Ruiz, Jose M.
Galán-Arriola, Carlos
Fernández-Jiménez, Rodrigo
Aguero, Jaume
Sánchez-González, Javier
García-Alvarez, Ana
Nuno-Ayala, Mario
Dubé, Gregory P.
Zafirelis, Zafiris
López-Martín, Gonzalo J.
Bernal, Juan A.
Lara-Pezzi, Enrique
Fuster, Valentín
Ibáñez, Borja
description Reperfusion, despite being required for myocardial salvage, is associated with additional injury. We hypothesize that infarct size (IS) will be reduced by a period of bloodless reperfusion with hemoglobin-based oxygen carriers (HBOC) before blood-flow restoration. In the pig model, we first characterized the impact of intracoronary perfusion with a fixed volume (600 ml) of a pre-oxygenated acellular HBOC, HBOC-201, on the healthy myocardium. HBOC-201 was administered through the lumen of the angioplasty balloon (i.e., distal to the occlusion site) immediately after onset of coronary occlusion at 1, 0.7, 0.4, or 0.2 ml/kg/min for 12, 17, 30, and 60 min, respectively, followed by blood-flow restoration. Outcome measures were systemic hemodynamics and LV performance assessed by the state-of-the-art cardiac magnetic resonance (CMR) imaging. The best performing HBOC-201 perfusion strategies were then tested for their impact on LV performance during myocardial infarction, in pigs subjected to 45 min mid-left anterior descending (LAD) coronary occlusion. At the end of the ischemia duration, pigs were randomized to regular reperfusion (blood-only reperfusion) vs. bloodless reperfusion (perfusion with pre-oxygenated HBOC-201 distal to the occlusion site), followed by blood-flow restoration. Hemodynamics and CMR-measured LV performance were assessed at 7- and 45-day follow-up. In modifications of the HBOC-201 procedure, glucose and insulin were included to support cardiac metabolism. A total of 66 pigs were included in this study. Twenty healthy pigs (5 per infusion protocol) were used in the study of healthy myocardium. Intracoronary administration of HBOC-201 (600 ml) at varying rates, including a flow of 0.4 ml/kg/min (corresponding to a maximum perfusion time of 30 min), did not damage the healthy myocardium. Slower perfusion (longer infusion time) was associated with permanent LV dysfunction and myocardial necrosis. A total of 46 pigs underwent MI induction. Compared with regular reperfusion, bloodless reperfusion with pre-oxygenated HBOC-201 alone increased IS. This effect was reversed by enrichment of pre-oxygenated HBOC-201 solution with glucose and insulin, resulting in no increase in IS or worsening of long-term ventricular function despite further delaying restoration of blood flow in the LAD. Bloodless reperfusion with a pre-oxygenated HBOC-201 solution supplemented with glucose and insulin is feasible and safe, but did not reduce infarct size. This stra
doi_str_mv 10.1007/s00395-017-0605-6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1877831880</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1877831880</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-fba28033d7903af2f6a152657f36b75f35918ffc86cfc3a039aba42fb814f03c3</originalsourceid><addsrcrecordid>eNqNkc9u1DAQxi1ERZfCA3BBlrhwMR3_iePlRldAkSr1AmfLccZtKide7KSw78BD4-0WhCpV4mJ7PL9vRjMfIa84vOMA7WkBkOuGAW8ZaGiYfkJWXMmGcQPyKVmBBGBGCXNMnpdyA8CV1vwZORaGG6OkWpFfZzGlPmIpNOMWc1jKkCb6Y5iv6XyNNP3cXeFEvct5wEzPzy43TACnw0SdX2ak4y7VZD-4WP-Cy36u-vfU0SndYqTb6OaQ8kjrQe_AtM1pxordIq3PDgvtMdYo716Qo-BiwZf39wn59unj1805u7j8_GXz4YJ5Bc3MQudEHVD27RqkCyJoxxuhmzZI3bVNkM2amxC80T546eqOXOeUCJ3hKoD08oS8PdSt_b8vWGY7DsVjjG7CtBTLTdsaWVcE_4HqtpFr0aqKvnmA3qQlT3WQO6oyRulK8QPlcyolY7DbPIwu7ywHu3fVHly11VW7d9XuNa_vKy_diP1fxR8bKyAOQKmp6QrzP60frfobedqt8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1867927846</pqid></control><display><type>article</type><title>Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>García-Ruiz, Jose M. ; Galán-Arriola, Carlos ; Fernández-Jiménez, Rodrigo ; Aguero, Jaume ; Sánchez-González, Javier ; García-Alvarez, Ana ; Nuno-Ayala, Mario ; Dubé, Gregory P. ; Zafirelis, Zafiris ; López-Martín, Gonzalo J. ; Bernal, Juan A. ; Lara-Pezzi, Enrique ; Fuster, Valentín ; Ibáñez, Borja</creator><creatorcontrib>García-Ruiz, Jose M. ; Galán-Arriola, Carlos ; Fernández-Jiménez, Rodrigo ; Aguero, Jaume ; Sánchez-González, Javier ; García-Alvarez, Ana ; Nuno-Ayala, Mario ; Dubé, Gregory P. ; Zafirelis, Zafiris ; López-Martín, Gonzalo J. ; Bernal, Juan A. ; Lara-Pezzi, Enrique ; Fuster, Valentín ; Ibáñez, Borja</creatorcontrib><description>Reperfusion, despite being required for myocardial salvage, is associated with additional injury. We hypothesize that infarct size (IS) will be reduced by a period of bloodless reperfusion with hemoglobin-based oxygen carriers (HBOC) before blood-flow restoration. In the pig model, we first characterized the impact of intracoronary perfusion with a fixed volume (600 ml) of a pre-oxygenated acellular HBOC, HBOC-201, on the healthy myocardium. HBOC-201 was administered through the lumen of the angioplasty balloon (i.e., distal to the occlusion site) immediately after onset of coronary occlusion at 1, 0.7, 0.4, or 0.2 ml/kg/min for 12, 17, 30, and 60 min, respectively, followed by blood-flow restoration. Outcome measures were systemic hemodynamics and LV performance assessed by the state-of-the-art cardiac magnetic resonance (CMR) imaging. The best performing HBOC-201 perfusion strategies were then tested for their impact on LV performance during myocardial infarction, in pigs subjected to 45 min mid-left anterior descending (LAD) coronary occlusion. At the end of the ischemia duration, pigs were randomized to regular reperfusion (blood-only reperfusion) vs. bloodless reperfusion (perfusion with pre-oxygenated HBOC-201 distal to the occlusion site), followed by blood-flow restoration. Hemodynamics and CMR-measured LV performance were assessed at 7- and 45-day follow-up. In modifications of the HBOC-201 procedure, glucose and insulin were included to support cardiac metabolism. A total of 66 pigs were included in this study. Twenty healthy pigs (5 per infusion protocol) were used in the study of healthy myocardium. Intracoronary administration of HBOC-201 (600 ml) at varying rates, including a flow of 0.4 ml/kg/min (corresponding to a maximum perfusion time of 30 min), did not damage the healthy myocardium. Slower perfusion (longer infusion time) was associated with permanent LV dysfunction and myocardial necrosis. A total of 46 pigs underwent MI induction. Compared with regular reperfusion, bloodless reperfusion with pre-oxygenated HBOC-201 alone increased IS. This effect was reversed by enrichment of pre-oxygenated HBOC-201 solution with glucose and insulin, resulting in no increase in IS or worsening of long-term ventricular function despite further delaying restoration of blood flow in the LAD. Bloodless reperfusion with a pre-oxygenated HBOC-201 solution supplemented with glucose and insulin is feasible and safe, but did not reduce infarct size. This strategy could be, however, used to deliver agents to the myocardium to treat or prevent ischemia/reperfusion injury before blood-flow restoration.</description><identifier>ISSN: 0300-8428</identifier><identifier>EISSN: 1435-1803</identifier><identifier>DOI: 10.1007/s00395-017-0605-6</identifier><identifier>PMID: 28188434</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Animals ; Cardiology ; Disease Models, Animal ; Heart - drug effects ; Hemodynamics - drug effects ; Hemoglobins - pharmacology ; Medicine ; Medicine &amp; Public Health ; Myocardial Infarction - complications ; Myocardial Reperfusion - methods ; Myocardial Reperfusion Injury - prevention &amp; control ; Original Contribution ; Random Allocation ; Swine</subject><ispartof>Basic research in cardiology, 2017-03, Vol.112 (2), p.17-17, Article 17</ispartof><rights>Springer-Verlag Berlin Heidelberg 2017</rights><rights>Basic Research in Cardiology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-fba28033d7903af2f6a152657f36b75f35918ffc86cfc3a039aba42fb814f03c3</citedby><cites>FETCH-LOGICAL-c405t-fba28033d7903af2f6a152657f36b75f35918ffc86cfc3a039aba42fb814f03c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00395-017-0605-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00395-017-0605-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28188434$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García-Ruiz, Jose M.</creatorcontrib><creatorcontrib>Galán-Arriola, Carlos</creatorcontrib><creatorcontrib>Fernández-Jiménez, Rodrigo</creatorcontrib><creatorcontrib>Aguero, Jaume</creatorcontrib><creatorcontrib>Sánchez-González, Javier</creatorcontrib><creatorcontrib>García-Alvarez, Ana</creatorcontrib><creatorcontrib>Nuno-Ayala, Mario</creatorcontrib><creatorcontrib>Dubé, Gregory P.</creatorcontrib><creatorcontrib>Zafirelis, Zafiris</creatorcontrib><creatorcontrib>López-Martín, Gonzalo J.</creatorcontrib><creatorcontrib>Bernal, Juan A.</creatorcontrib><creatorcontrib>Lara-Pezzi, Enrique</creatorcontrib><creatorcontrib>Fuster, Valentín</creatorcontrib><creatorcontrib>Ibáñez, Borja</creatorcontrib><title>Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery</title><title>Basic research in cardiology</title><addtitle>Basic Res Cardiol</addtitle><addtitle>Basic Res Cardiol</addtitle><description>Reperfusion, despite being required for myocardial salvage, is associated with additional injury. We hypothesize that infarct size (IS) will be reduced by a period of bloodless reperfusion with hemoglobin-based oxygen carriers (HBOC) before blood-flow restoration. In the pig model, we first characterized the impact of intracoronary perfusion with a fixed volume (600 ml) of a pre-oxygenated acellular HBOC, HBOC-201, on the healthy myocardium. HBOC-201 was administered through the lumen of the angioplasty balloon (i.e., distal to the occlusion site) immediately after onset of coronary occlusion at 1, 0.7, 0.4, or 0.2 ml/kg/min for 12, 17, 30, and 60 min, respectively, followed by blood-flow restoration. Outcome measures were systemic hemodynamics and LV performance assessed by the state-of-the-art cardiac magnetic resonance (CMR) imaging. The best performing HBOC-201 perfusion strategies were then tested for their impact on LV performance during myocardial infarction, in pigs subjected to 45 min mid-left anterior descending (LAD) coronary occlusion. At the end of the ischemia duration, pigs were randomized to regular reperfusion (blood-only reperfusion) vs. bloodless reperfusion (perfusion with pre-oxygenated HBOC-201 distal to the occlusion site), followed by blood-flow restoration. Hemodynamics and CMR-measured LV performance were assessed at 7- and 45-day follow-up. In modifications of the HBOC-201 procedure, glucose and insulin were included to support cardiac metabolism. A total of 66 pigs were included in this study. Twenty healthy pigs (5 per infusion protocol) were used in the study of healthy myocardium. Intracoronary administration of HBOC-201 (600 ml) at varying rates, including a flow of 0.4 ml/kg/min (corresponding to a maximum perfusion time of 30 min), did not damage the healthy myocardium. Slower perfusion (longer infusion time) was associated with permanent LV dysfunction and myocardial necrosis. A total of 46 pigs underwent MI induction. Compared with regular reperfusion, bloodless reperfusion with pre-oxygenated HBOC-201 alone increased IS. This effect was reversed by enrichment of pre-oxygenated HBOC-201 solution with glucose and insulin, resulting in no increase in IS or worsening of long-term ventricular function despite further delaying restoration of blood flow in the LAD. Bloodless reperfusion with a pre-oxygenated HBOC-201 solution supplemented with glucose and insulin is feasible and safe, but did not reduce infarct size. This strategy could be, however, used to deliver agents to the myocardium to treat or prevent ischemia/reperfusion injury before blood-flow restoration.</description><subject>Animals</subject><subject>Cardiology</subject><subject>Disease Models, Animal</subject><subject>Heart - drug effects</subject><subject>Hemodynamics - drug effects</subject><subject>Hemoglobins - pharmacology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Myocardial Infarction - complications</subject><subject>Myocardial Reperfusion - methods</subject><subject>Myocardial Reperfusion Injury - prevention &amp; control</subject><subject>Original Contribution</subject><subject>Random Allocation</subject><subject>Swine</subject><issn>0300-8428</issn><issn>1435-1803</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkc9u1DAQxi1ERZfCA3BBlrhwMR3_iePlRldAkSr1AmfLccZtKide7KSw78BD4-0WhCpV4mJ7PL9vRjMfIa84vOMA7WkBkOuGAW8ZaGiYfkJWXMmGcQPyKVmBBGBGCXNMnpdyA8CV1vwZORaGG6OkWpFfZzGlPmIpNOMWc1jKkCb6Y5iv6XyNNP3cXeFEvct5wEzPzy43TACnw0SdX2ak4y7VZD-4WP-Cy36u-vfU0SndYqTb6OaQ8kjrQe_AtM1pxordIq3PDgvtMdYo716Qo-BiwZf39wn59unj1805u7j8_GXz4YJ5Bc3MQudEHVD27RqkCyJoxxuhmzZI3bVNkM2amxC80T546eqOXOeUCJ3hKoD08oS8PdSt_b8vWGY7DsVjjG7CtBTLTdsaWVcE_4HqtpFr0aqKvnmA3qQlT3WQO6oyRulK8QPlcyolY7DbPIwu7ywHu3fVHly11VW7d9XuNa_vKy_diP1fxR8bKyAOQKmp6QrzP60frfobedqt8Q</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>García-Ruiz, Jose M.</creator><creator>Galán-Arriola, Carlos</creator><creator>Fernández-Jiménez, Rodrigo</creator><creator>Aguero, Jaume</creator><creator>Sánchez-González, Javier</creator><creator>García-Alvarez, Ana</creator><creator>Nuno-Ayala, Mario</creator><creator>Dubé, Gregory P.</creator><creator>Zafirelis, Zafiris</creator><creator>López-Martín, Gonzalo J.</creator><creator>Bernal, Juan A.</creator><creator>Lara-Pezzi, Enrique</creator><creator>Fuster, Valentín</creator><creator>Ibáñez, Borja</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QO</scope></search><sort><creationdate>20170301</creationdate><title>Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery</title><author>García-Ruiz, Jose M. ; Galán-Arriola, Carlos ; Fernández-Jiménez, Rodrigo ; Aguero, Jaume ; Sánchez-González, Javier ; García-Alvarez, Ana ; Nuno-Ayala, Mario ; Dubé, Gregory P. ; Zafirelis, Zafiris ; López-Martín, Gonzalo J. ; Bernal, Juan A. ; Lara-Pezzi, Enrique ; Fuster, Valentín ; Ibáñez, Borja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-fba28033d7903af2f6a152657f36b75f35918ffc86cfc3a039aba42fb814f03c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Cardiology</topic><topic>Disease Models, Animal</topic><topic>Heart - drug effects</topic><topic>Hemodynamics - drug effects</topic><topic>Hemoglobins - pharmacology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Myocardial Infarction - complications</topic><topic>Myocardial Reperfusion - methods</topic><topic>Myocardial Reperfusion Injury - prevention &amp; control</topic><topic>Original Contribution</topic><topic>Random Allocation</topic><topic>Swine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García-Ruiz, Jose M.</creatorcontrib><creatorcontrib>Galán-Arriola, Carlos</creatorcontrib><creatorcontrib>Fernández-Jiménez, Rodrigo</creatorcontrib><creatorcontrib>Aguero, Jaume</creatorcontrib><creatorcontrib>Sánchez-González, Javier</creatorcontrib><creatorcontrib>García-Alvarez, Ana</creatorcontrib><creatorcontrib>Nuno-Ayala, Mario</creatorcontrib><creatorcontrib>Dubé, Gregory P.</creatorcontrib><creatorcontrib>Zafirelis, Zafiris</creatorcontrib><creatorcontrib>López-Martín, Gonzalo J.</creatorcontrib><creatorcontrib>Bernal, Juan A.</creatorcontrib><creatorcontrib>Lara-Pezzi, Enrique</creatorcontrib><creatorcontrib>Fuster, Valentín</creatorcontrib><creatorcontrib>Ibáñez, Borja</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><jtitle>Basic research in cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García-Ruiz, Jose M.</au><au>Galán-Arriola, Carlos</au><au>Fernández-Jiménez, Rodrigo</au><au>Aguero, Jaume</au><au>Sánchez-González, Javier</au><au>García-Alvarez, Ana</au><au>Nuno-Ayala, Mario</au><au>Dubé, Gregory P.</au><au>Zafirelis, Zafiris</au><au>López-Martín, Gonzalo J.</au><au>Bernal, Juan A.</au><au>Lara-Pezzi, Enrique</au><au>Fuster, Valentín</au><au>Ibáñez, Borja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery</atitle><jtitle>Basic research in cardiology</jtitle><stitle>Basic Res Cardiol</stitle><addtitle>Basic Res Cardiol</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>112</volume><issue>2</issue><spage>17</spage><epage>17</epage><pages>17-17</pages><artnum>17</artnum><issn>0300-8428</issn><eissn>1435-1803</eissn><abstract>Reperfusion, despite being required for myocardial salvage, is associated with additional injury. We hypothesize that infarct size (IS) will be reduced by a period of bloodless reperfusion with hemoglobin-based oxygen carriers (HBOC) before blood-flow restoration. In the pig model, we first characterized the impact of intracoronary perfusion with a fixed volume (600 ml) of a pre-oxygenated acellular HBOC, HBOC-201, on the healthy myocardium. HBOC-201 was administered through the lumen of the angioplasty balloon (i.e., distal to the occlusion site) immediately after onset of coronary occlusion at 1, 0.7, 0.4, or 0.2 ml/kg/min for 12, 17, 30, and 60 min, respectively, followed by blood-flow restoration. Outcome measures were systemic hemodynamics and LV performance assessed by the state-of-the-art cardiac magnetic resonance (CMR) imaging. The best performing HBOC-201 perfusion strategies were then tested for their impact on LV performance during myocardial infarction, in pigs subjected to 45 min mid-left anterior descending (LAD) coronary occlusion. At the end of the ischemia duration, pigs were randomized to regular reperfusion (blood-only reperfusion) vs. bloodless reperfusion (perfusion with pre-oxygenated HBOC-201 distal to the occlusion site), followed by blood-flow restoration. Hemodynamics and CMR-measured LV performance were assessed at 7- and 45-day follow-up. In modifications of the HBOC-201 procedure, glucose and insulin were included to support cardiac metabolism. A total of 66 pigs were included in this study. Twenty healthy pigs (5 per infusion protocol) were used in the study of healthy myocardium. Intracoronary administration of HBOC-201 (600 ml) at varying rates, including a flow of 0.4 ml/kg/min (corresponding to a maximum perfusion time of 30 min), did not damage the healthy myocardium. Slower perfusion (longer infusion time) was associated with permanent LV dysfunction and myocardial necrosis. A total of 46 pigs underwent MI induction. Compared with regular reperfusion, bloodless reperfusion with pre-oxygenated HBOC-201 alone increased IS. This effect was reversed by enrichment of pre-oxygenated HBOC-201 solution with glucose and insulin, resulting in no increase in IS or worsening of long-term ventricular function despite further delaying restoration of blood flow in the LAD. Bloodless reperfusion with a pre-oxygenated HBOC-201 solution supplemented with glucose and insulin is feasible and safe, but did not reduce infarct size. This strategy could be, however, used to deliver agents to the myocardium to treat or prevent ischemia/reperfusion injury before blood-flow restoration.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28188434</pmid><doi>10.1007/s00395-017-0605-6</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-8428
ispartof Basic research in cardiology, 2017-03, Vol.112 (2), p.17-17, Article 17
issn 0300-8428
1435-1803
language eng
recordid cdi_proquest_miscellaneous_1877831880
source MEDLINE; SpringerLink Journals
subjects Animals
Cardiology
Disease Models, Animal
Heart - drug effects
Hemodynamics - drug effects
Hemoglobins - pharmacology
Medicine
Medicine & Public Health
Myocardial Infarction - complications
Myocardial Reperfusion - methods
Myocardial Reperfusion Injury - prevention & control
Original Contribution
Random Allocation
Swine
title Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T07%3A27%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bloodless%20reperfusion%20with%20the%20oxygen%20carrier%20HBOC-201%20in%20acute%20myocardial%20infarction:%20a%20novel%20platform%20for%20cardioprotective%20probes%20delivery&rft.jtitle=Basic%20research%20in%20cardiology&rft.au=Garc%C3%ADa-Ruiz,%20Jose%20M.&rft.date=2017-03-01&rft.volume=112&rft.issue=2&rft.spage=17&rft.epage=17&rft.pages=17-17&rft.artnum=17&rft.issn=0300-8428&rft.eissn=1435-1803&rft_id=info:doi/10.1007/s00395-017-0605-6&rft_dat=%3Cproquest_cross%3E1877831880%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1867927846&rft_id=info:pmid/28188434&rfr_iscdi=true